Acrivon Therapeutics, Inc. ACRV 深 沪
等待开盘 10-14 09:30:00 美东时间
1.75
-0.150
-7.89%
华盛通- 最 高1.8721
- 今 开1.86
- 成交量 47.73万股
- 最 低 1.74
- 昨 收 1.90
- 总市值 7499.34万
- 52周最高 3.56
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 1.27
- 委 比 16.82%
- 总股本 4285.34万
- 历史最高 25.47
- 量 比 2.00
- 振 幅 6.95%
- 历史最低 1.05
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
Acrivon Therapeutics announced that its CEO, Peter Blume-Jensen, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference. The company utilizes its proprietary Generative Phosphoproteomics AP3 platform for drug discovery and development. Acrivon is advancing ACR-368, a CHK1/CHK2 inhibitor in a Phase 2 trial for endometrial cancer, with FDA Fast Track and Breakthrough Device designations. Additionally, ACR-2316, a WEE1/P...
09-02 12:00
Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 21.82 percent increase over losses of $(0.55) per share from the same period last year.
08-13 04:23
Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study
Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly regimen (3 days on/4 days off) at 120 mg and 160 mg QD dose levels selected for randomized dose optimizati...
08-05 20:32
Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24
Presentations and Details Oral Podium Presentation Title: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug Discovery Presenter: Lei Shi, Ph.D., Director and Head, AP3 Pathway Discovery, Acrivon Therapeutics Session: Biotech Spotlight...
07-22 04:32
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics granted an employee 111,150 stock options under its 2023 Inducement Plan, vesting 25% after one year and monthly thereafter. The company's Generative Phosphoproteomics AP3 platform enables precision medicine discovery. Acrivon is advancing ACR-368 in a Phase 2 trial for endometrial cancer and developing ACR-2316, a WEE1/PKMYT1 inhibitor, with promising early data.
05-15 20:00
Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 3.92 percent increase over losses of $(0.51) per share
05-14 04:24
Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026
Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics
04-18 04:03
